Asset profile
Binimetinib
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Non-Small Cell Lung Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
This drug's registrational program predates the public trial registry, so its Featured trials section is empty by necessity, not by omission.
Featured evidence outside covered markets:NCT01763164 · Metastatic or Unresectable Cutaneous Melanoma · Phase 3 · met primary endpoint · Partial signalNCT01337765 · Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor · Phase 1 · completed · Weak signalInCITe (NCT03971409) · Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma · Phase 2 · ungraded
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
62 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Binimetinib: this drug | Approved | Small molecule | MEK1/2 | ||
| Trametinib | Approved | Small molecule | MEK1/2 | ||
| Luvometinib | Phase 3 | Small molecule | MEK1/2 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK |
…and 47 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(27 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4)
October 2026 (1)
Phase 3MelanomaActive not recruiting
Est. primary completion 2026-10-30 · NCT04657991 · CT.gov ↗
What to watch
November 2026 (1)
Phase 1/2Gastrointestinal Stromal Tumor (GIST)Active not recruiting
Est. primary completion 2026-11 · NCT01991379 · CT.gov ↗
What to watch
2027 (15)
January 2027 (2)
Phase 1/2Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid TumorsRecruiting
Est. primary completion 2027-01-29 · NCT03947385 · CT.gov ↗
What to watch
Phase 2Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer …Active not recruiting
Est. primary completion 2027-01-31 · NCT03971409 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8Recruiting
Est. primary completion 2027-02-02 · NCT05026983 · CT.gov ↗
What to watch
Phase 2Low-grade Glioma, Pancreatic CancerRecruiting
Est. primary completion 2027-02-28 · NCT06159478 · CT.gov ↗
What to watch
March 2027 (2)
Phase 1Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm …Recruiting
Est. primary completion 2027-03-14 · NCT05111561 · CT.gov ↗
What to watch
Phase 3MelanomaActive not recruiting
Est. primary completion 2027-03-31 · NCT05270044 · CT.gov ↗
What to watch
April 2027 (2)
Phase 1Melanoma Stage III, Melanoma Stage IV, BRAF V600 MutationRecruiting
Est. primary completion 2027-04 · NCT04741997 · CT.gov ↗
What to watch
Phase 2Adamantinous Craniopharyngioma, Recurrent Adamantinomatous CraniopharyngiomaRecruiting
Est. primary completion 2027-04-10 · NCT05286788 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Melanoma Stage III, Melanoma Stage IVRecruiting
Est. primary completion 2027-05-31 · NCT04598009 · CT.gov ↗
What to watch
June 2027 (2)
Phase 3Biliary Tract NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05615818 · CT.gov ↗
What to watch
Phase 2Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma …Recruiting
Est. primary completion 2027-06-30 · NCT04511013 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-08-31 · NCT05355701 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 …Active not recruiting
Est. primary completion 2027-12-08 · NCT02910700 · CT.gov ↗
What to watch
Phase 2BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma …Active not recruiting
Est. primary completion 2027-12-30 · NCT04061980 · CT.gov ↗
What to watch
Phase 2Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
2028 (5)
January 2028 (1)
Phase 2Melanoma BRAF V600E/K Mutated, Melanoma and Brain MetastasesRecruiting
Est. primary completion 2028-01 · NCT06887088 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Hairy Cell LeukemiaRecruiting
Est. primary completion 2028-04-30 · NCT04322383 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1Metastatic Melanoma, BRAF Gene MutationRecruiting
Est. primary completion 2028-07-01 · NCT04903119 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8 …Active not recruiting
Est. primary completion 2028-08-26 · NCT05554367 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-11-30 · NCT04913285 · CT.gov ↗
What to watch
2029 (2)
2030 (1)
July 2030 (1)
Phase 2Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2030-07-01 · NCT05564377 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.